Esperion Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Esperion Therapeutics
ESPR Stock  USD 1.58  0.04  2.60%   
Esperion Therapeutics financial statements provide useful quarterly and yearly information to potential Esperion Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Esperion Therapeutics financial statements helps investors assess Esperion Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Esperion Therapeutics' valuation are summarized below:
Gross Profit
217.5 M
Profit Margin
(0.16)
Market Capitalization
304.7 M
Enterprise Value Revenue
1.3768
Revenue
332.3 M
There are over one hundred nineteen available fundamental signals for Esperion Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to verify Esperion Therapeutics' prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Market Cap is likely to grow to about 510.9 M, while Enterprise Value is likely to drop slightly above 538.4 M.

Esperion Therapeutics Total Revenue

377.84 Million

Check Esperion Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Esperion Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.4 K, Interest Expense of 62.2 M or Gross Profit of 327.3 M, as well as many indicators such as Price To Sales Ratio of 1.18, Dividend Yield of 0.0 or Days Sales Outstanding of 84.78. Esperion financial statements analysis is a perfect complement when working with Esperion Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Esperion Therapeutics Correlation against competitors.
To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

Esperion Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets192.8 M343.8 M196.3 M
Slightly volatile
Short and Long Term Debt Total312.5 M297.6 M119.4 M
Slightly volatile
Other Current Liabilities135.2 M128.7 M33 M
Slightly volatile
Total Current Liabilities258.5 M246.2 M71 M
Slightly volatile
Property Plant And Equipment Net6.1 M5.8 M2.2 M
Slightly volatile
Accounts Payable54.2 M51.6 M21 M
Slightly volatile
Cash95 M144.8 M91.8 M
Slightly volatile
Non Current Assets Total5.5 M5.8 M20.3 M
Very volatile
Cash And Short Term Investments95.5 M144.8 M92.1 M
Slightly volatile
Common Stock Total Equity90.6 K86.2 K36.1 K
Slightly volatile
Common Stock Shares Outstanding196.5 M187.2 M47.4 M
Slightly volatile
Other Current Assets19.5 M18.6 M6.6 M
Slightly volatile
Total Liabilities769.2 M732.5 M258.2 M
Slightly volatile
Property Plant And Equipment Gross8.2 M7.8 M2.4 M
Slightly volatile
Total Current Assets172.2 M338 M175.1 M
Slightly volatile
Short Term Debt60.2 M57.3 M14.8 M
Slightly volatile
Common Stock205.8 K196 K52.9 K
Slightly volatile
Intangible Assets47.9 K50.4 K270.1 K
Slightly volatile
Other Liabilities542.1 K570.6 K1.2 M
Slightly volatile
Property Plant Equipment179.2 K188.6 K481.3 K
Very volatile
Current Deferred Revenue4.8 M8.5 M3.6 M
Slightly volatile
Capital Surpluse676.3 M1.2 B597.1 M
Slightly volatile
Long Term Debt Total216.6 M206.3 M106.5 M
Slightly volatile
Short and Long Term Debt65.9 M62.8 M22.8 M
Slightly volatile
Net Working Capital119.3 M91.8 M156.7 M
Slightly volatile
Capital Stock205.8 K196 K59.5 K
Slightly volatile
Capital Lease Obligations3.7 M5.3 M2.4 M
Slightly volatile
Non Current Liabilities Other145.1 M246 M130.8 M
Pretty Stable
Net Receivables43.5 M80.1 M22.8 M
Slightly volatile

Esperion Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses145.3 M277.9 M152.3 M
Slightly volatile
Research Development74.4 M46.2 M76.7 M
Slightly volatile
Total Operating Expenses139.9 M277.9 M146.5 M
Slightly volatile
Selling General Administrative171.2 M163.1 M68.4 M
Slightly volatile
Non Operating Income Net Other2.3 M3 M1.7 M
Slightly volatile
Reconciled Depreciation59.9 K63 K292.5 K
Very volatile
Interest Income3.5 M4 M4.3 M
Slightly volatile
Selling And Marketing Expenses12 M14 M17.4 M
Slightly volatile

Esperion Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow87.8 M82.2 M86.1 M
Slightly volatile
End Period Cash Flow98.2 M144.8 M95.2 M
Slightly volatile
Stock Based Compensation15.2 M12 M13.1 M
Slightly volatile
Change To Netincome18.7 M17.5 M14.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.181.23921.3 K
Slightly volatile
Days Sales Outstanding84.7888.024750.835
Slightly volatile
Average Payables775.1 K1.2 M1.2 M
Slightly volatile
Stock Based Compensation To Revenue0.03430.03610.1022
Slightly volatile
Inventory Turnover0.40.590.2787
Slightly volatile
Days Of Inventory On Hand1.2 K6371.9 K
Slightly volatile
Payables Turnover0.771.230.8561
Pretty Stable
Sales General And Administrative To Revenue0.690.980.5237
Slightly volatile
Research And Ddevelopement To Revenue0.130.1391682
Slightly volatile
Capex To Revenue0.0010.001141.9109
Slightly volatile
Cash Per Share0.730.77345.0247
Very volatile
Days Payables Outstanding2923087.1 K
Very volatile
Income Quality0.840.45710.7491
Slightly volatile
Intangibles To Total Assets2.0E-42.0E-40.005
Slightly volatile
Current Ratio1.31.37277.2464
Slightly volatile
Receivables Turnover6.724.146613.811
Slightly volatile
Capex Per Share0.00190.00190.1111
Slightly volatile
Revenue Per Share1.691.775464.5573
Slightly volatile
Interest Debt Per Share1.871.90652.4424
Slightly volatile
Debt To Assets0.640.86560.8207
Very volatile
Operating Cycle83.6288.02471.9 K
Slightly volatile
Days Of Payables Outstanding2923087.1 K
Very volatile
Quick Ratio0.940.98897.1098
Slightly volatile
Net Income Per E B T0.91.111.1121
Pretty Stable
Cash Ratio0.560.58793.8731
Slightly volatile
Days Of Inventory Outstanding1.2 K6371.9 K
Slightly volatile
Days Of Sales Outstanding84.7888.024750.835
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.171.0478
Pretty Stable
Fixed Asset Turnover54.7457.623411.7 K
Slightly volatile
Debt Ratio0.640.86560.8207
Very volatile
Price Sales Ratio1.181.23921.3 K
Slightly volatile
Asset Turnover0.920.966512.5895
Slightly volatile

Esperion Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap510.9 M411.8 M668.6 M
Pretty Stable
Enterprise Value538.4 M564.6 M687.2 M
Slightly volatile

Esperion Fundamental Market Drivers

Forward Price Earnings1.345
Cash And Short Term Investments144.8 M

Esperion Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Esperion Therapeutics Financial Statements

Esperion Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Esperion Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Esperion Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Esperion Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue8.5 M4.8 M
Cost Of Revenue68.6 M51.2 M
Total Revenue332.3 M377.8 M
Stock Based Compensation To Revenue 0.04  0.03 
Sales General And Administrative To Revenue 0.98  0.69 
Research And Ddevelopement To Revenue 0.14  0.13 
Revenue Per Share 1.78  1.69 
Ebit Per Revenue 0.16  0.17 

Pair Trading with Esperion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Esperion Stock

  0.75ME 23Andme HoldingPairCorr

Moving against Esperion Stock

  0.71VALN Valneva SE ADRPairCorr
  0.58DVAX Dynavax TechnologiesPairCorr
  0.53DMAC DiaMedica TherapeuticsPairCorr
  0.43VIGL Vigil NeurosciencePairCorr
  0.34EQ EquilliumPairCorr
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY